MENU
Showcases Stock ranks Forex

Pmv Pharmaceuticals Inc (PMVP)
1.71  0.02 (1.18%) 04-25 16:00
Open: 1.67 Pre. Close: 1.69
High: 1.72 Low: 1.655
Volume: 310,963 Market Cap: 88(M)
Stock Technical Analysis
Overall:     
Target: Six months: 2.16
One year: 2.52
Support: Support1: 1.63
Support2: 1.49
Resistance: Resistance1: 1.85
Resistance2: 2.16
Pivot: 1.64
Moving Averages: MA(5): 1.71
MA(20): 1.66
MA(100): 1.96
MA(250): 3.96
MACD: MACD(12,26):
Signal(12,26,9): -0.02
%K %D: %K(14,3): 68.06
%D(3): 67.35
RSI: RSI(14): 51.90
52-Week: High: 9.72
Low: 1.175
Change(%): -62.3
Average Vol(K): 3-Month: 577
10-Days: 525
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 1.721 - 1.729 1.729 - 1.737
Low: 1.629 - 1.639 1.639 - 1.647
Close: 1.695 - 1.709 1.709 - 1.723
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.

[ PMVP ] has closed below upper band by 29.3%. Bollinger Bands are 50.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 59 bars. This is a sign that the market may be about to initiate a new trend.
Company profile
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
Stock chart
Stock News
Sat, 20 Apr 2024
Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth - Simply Wall St

Fri, 19 Apr 2024
PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

Fri, 12 Apr 2024
PMV Pharmaceuticals (NASDAQ:PMVP) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat

Mon, 18 Mar 2024
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late ... - GlobeNewswire

Thu, 29 Feb 2024
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights - GlobeNewswire

Thu, 18 Jan 2024
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway - Yahoo Finance

Financial Analysis
Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Neutral
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 51.44
Shares Float (M) 41.01
% Held by Insiders 2.95
% Held by Institutions 99.47
Shares Short (K) 2600
Shares Short Prior Month (K) 1980
Stock Financials
EPS -1.440
Book Value (p.s.) 4.390
Profit Margin
Operating Margin
Return on Assets (ttm) -19.2
Return on Equity (ttm) -29.2
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -1.533
Qtrly Earnings Growth
Operating Cash Flow (M) -55.66
Levered Free Cash Flow (M) -32.94
Stock Valuation
PE Ratio -1.19
PEG Ratio -0.05
Price to Book value 0.39
Price to Sales
Price to Cash Flow -1.58
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android